Abstract
The progressive increase of infections produced by extensively drug-resistant carbapenemase-producing Klebsiella pneumoniae (XDR-CPKP) represents an important threat to public health. Unfortunately, optimal therapeutic options are scarce. Retrospective studies have recommended combined therapy with more than one antibiotic and, more recently, a double-carbapenem regimen has been reported to be an effective alternative therapy. Here, we describe an episode of sepsis in an immunocompromised patient after allogeneic hematopoietic stem cell transplantation, caused by an XDR-CPKP. Several in vitro synergy tests revealed a synergistic effect combining ertapenem and meropenem, which were used as combination therapy achieving clinical and microbiological success.
Keywords:
DCR; XDR; bloodstream infection; ertapenem; meropenem; sepsis.
MeSH terms
-
Adult
-
Anti-Bacterial Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Drug Combinations
-
Ertapenem
-
Female
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Immunocompromised Host*
-
Klebsiella Infections / drug therapy*
-
Klebsiella Infections / etiology
-
Klebsiella Infections / immunology
-
Klebsiella Infections / microbiology
-
Klebsiella pneumoniae
-
Meropenem
-
Sarcoma, Myeloid / immunology
-
Sarcoma, Myeloid / pathology
-
Sarcoma, Myeloid / therapy
-
Sepsis / drug therapy*
-
Sepsis / etiology
-
Sepsis / immunology
-
Sepsis / microbiology
-
Thienamycins / therapeutic use*
-
Transplantation, Homologous
-
Treatment Outcome
-
beta-Lactams / therapeutic use*
Substances
-
Anti-Bacterial Agents
-
Drug Combinations
-
Thienamycins
-
beta-Lactams
-
Meropenem
-
Ertapenem